Gilead had a very robust second quarter with total product sales of $5.7 billion, up 7% year over year, excluding Veklury. The company managed to deliver an all-around beat powered by HIV, cell therapy, and Trodelvy, partially offset by HCV. Sequentially, total product sales excluding Veklury increased by 14%, driven by seasonal pricing and inventory dynamics, especially in their HIV business, and increased demand across the whole portfolio. Despite generic and other market players, Descovy's sh ....
30 Aug 2022
Gilead Sciences: The MiroBio Acquisition & Other Drivers, Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (08/22)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Gilead Sciences: The MiroBio Acquisition & Other Drivers, Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (08/22)
- Published:
30 Aug 2022 -
Author:
Ishan Majumdar -
Pages:
27
Gilead had a very robust second quarter with total product sales of $5.7 billion, up 7% year over year, excluding Veklury. The company managed to deliver an all-around beat powered by HIV, cell therapy, and Trodelvy, partially offset by HCV. Sequentially, total product sales excluding Veklury increased by 14%, driven by seasonal pricing and inventory dynamics, especially in their HIV business, and increased demand across the whole portfolio. Despite generic and other market players, Descovy's sh ....